Part-Time
Global life sciences R&D services
No salary listed
Coral Springs, FL, USA
In Person
Travel to additional sites may be required.
See people who can refer or advise you
Labcorp provides end-to-end R&D services for life sciences and agricultural clients, including crop protection, with testing and regulatory support. It runs physicochemical analyses, safety assessments, and inhalation toxicology studies using specialized labs to evaluate inhaled substances. It differentiates itself with a global footprint and an integrated set of services across the product lifecycle, including regulatory submissions. Its goal is to help clients bring safe, effective products to market efficiently by applying rigorous science and scalable testing.
Company Size
10,001+
Company Stage
IPO
Headquarters
Burlington, Vermont
Founded
1976
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
Unlimited Paid Time Off
Tuition Reimbursement
Employee Stock Purchase Plan
Labcorp NACHC alliance to back health centre leaders. The Labcorp NACHC alliance, unveiled on 18 August, commits the diagnostics giant Labcorp (LH) to a long-term partnership with NACHC, the umbrella body for the country's community health centres, aimed at strengthening clinical leadership and using diagnostic data to close gaps in care across a network that treats more than 52 million patients a year, the two organisations said in a joint release. The centrepiece is a new "NACHC Leadership Exchange for Chief Medical Officers", a programme designed to support current and rising clinical leaders at health centres nationwide. Beyond training, the alliance covers practice-improvement work and the use of de-identified Labcorp data - patient information stripped of anything that could identify an individual - to help health centres track quality metrics and close gaps in care. The scope is wide: NACHC represents 1,526 community health centres serving 52.3 million patients across the US, figures confirmed in both the original release and syndicated coverage from Benzinga the same day. NACHC's chief executive, Kyu Rhee, is quoted in the release describing strong clinical leadership as essential to running a network of that size, underlining that the deal is being pitched as a workforce and quality initiative rather than a straightforward commercial supply arrangement. Why this Labcorp NACHC alliance didn't need an 8-K. Investors searching EDGAR for a formal disclosure of the tie-up will not find one. The only SEC filing touching Labcorp around this date is a Form 4 - an insider transaction report - filed by Kerrii B. Anderson on 18 August, hours after the announcement; the filing itself discloses no share counts or dollar values and has nothing evident to do with the NACHC partnership. That absence of a material-event filing is itself informative: a strategic alliance built around leadership training and data-sharing, rather than a capital commitment, an acquisition or a revenue guarantee, does not cross the threshold that would require Labcorp to tell shareholders formally that something financially significant has happened. That fits a pattern. Labcorp has built out a string of similar association-level tie-ups, including an earlier collaboration with the New Jersey Primary Care Association aimed at advancing value-based care among that state's community health centres, according to the company's own press materials. It has also been more actively acquisitive elsewhere: in late 2025 Labcorp completed a deal to acquire select outreach laboratory assets from Community Health Systems, according to the company's investor relations disclosures. Read together, the NACHC alliance looks less like an isolated PR moment and more like another rung in a deliberate ladder of provider and association partnerships that widen Labcorp's footprint in community and value-based care without necessarily moving the needle on near-term revenue. The numbers behind the announcement. None of this changes the financial picture much on its own, but that picture has been improving steadily. Labcorp's quarterly revenue has risen in every period tracked since the first quarter of 2024, climbing from $3,176.6m then to $3,731.1m in the second quarter of 2026, according to filings with the SEC. Net income over the same run climbed from $228m to $298.7m, while diluted earnings per share rose from $2.69 to $3.64 - an increase of more than one-third. That earnings trajectory is the backdrop against which a non-material partnership announcement like this one lands: it is unlikely to move estimates, but it reinforces a growth story that has, so far, been running quarter after quarter without interruption. The shares themselves gave no hint that anything was pending. Labcorp last traded at $328.9063 as of 17 August, before the alliance was announced the following morning, up 0.97% on the day and 5.24% over the preceding 20 trading days, according to consolidated exchange data. Short-selling activity - the share of daily volume attributable to bets that the stock will fall - was similarly unremarkable, with FINRA's short-volume ratio at 0.492 on 17 August, sitting squarely within the 0.485-to-0.536 range seen through most of the prior fortnight, aside from a brief spike above 0.7 in late July that had already faded. There is no sign in the trading data that anyone was positioning ahead of the news, which is consistent with an announcement of this kind: strategically sensible, operationally meaningful for the health centres involved, but not the sort of disclosure that moves a large-cap diagnostics stock. What the alliance is meant to achieve. For NACHC's member centres, the practical value lies less in headline figures and more in capacity-building: chief medical officers at community health centres are often stretched across clinical, administrative and quality-improvement duties simultaneously, and a structured leadership programme backed by a national diagnostics network gives them a resource many smaller centres could not otherwise access. The data-sharing element - using de-identified results to flag care gaps - could, if it works as described, help centres identify patients who have missed screenings or follow-up tests without Labcorp handing over anything that would raise privacy concerns. Whether the alliance produces measurable results, in the form of improved screening rates or leadership retention at health centres, will only become clear over the coming quarters, and neither organisation has attached specific targets or a public timeline to those outcomes. What is documented, for now, is the scope of the commitment and the network it covers - 1,526 health centres, 52.3 million patients - alongside a company whose underlying lab-testing business has kept expanding revenue and earnings every quarter through the period the deal was struck. This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.
Labcorp and NACHC launch strategic alliance to strengthen Health Center leadership and advance Community Health. 18 Aug 2026 Collaboration will support leadership development, practice improvement and innovation across the nation's Community Health Centers BURLINGTON, N.C. and BETHESDA, Md., Aug. 18, 2026 /PRNewswire/ - Labcorpopens in a new tab (NYSE: LH), a global leader of innovative and comprehensive laboratory services, and the National Association of Community Health Centersopens in a new tab (NACHC) today announced a strategic alliance to strengthen leadership development, support practice improvement and advance community health initiatives across the nation's Community Health Center (CHC) network. As part of the collaboration, the organizations are launching the NACHC Leadership Exchange for Chief Medical Officers, designed to support current and emerging clinical leaders serving health centers nationwide. CHCs make up the largest primary care network in the U.S., serving up to 1 in 7 Americans, including 1 in 3 in rural America. Through the alliance, Labcorp and NACHC will combine their respective expertise to help CHCs enhance clinical leadership, improve healthcare delivery, and sustain and expand strong health outcomes in communities across the country. "Community Health Centers serve as the healthcare home for 52.3 million patients across the country, and strong clinical leadership is essential to meeting growing demands for affordable, comprehensive and effective care," said Kyu Rhee, M.D., MPP, president and CEO of NACHC. "Through this alliance with Labcorp, we are creating new opportunities for clinicians to share best practices and advance innovative approaches that will help health centers improve outcomes for the patients and communities they serve." The strategic alliance establishes a long-term framework for collaboration between Labcorp and NACHC, bringing together NACHC's leadership and reach across 1,526 CHCs and Labcorp's expertise in diagnostics, analytics and community health. In addition to leadership development, the organizations will collaborate on educational initiatives, practice improvement efforts, evidence generation and leverage de-identified laboratory data to help CHCs strengthen quality performance, close gaps in care and improve patient outcomes. A key component of the collaboration is the launch of the NACHC Leadership Exchange for Chief Medical Officers (CMOs), a leadership development program created by NACHC with support and subject matter expertise from Labcorp. The program is designed to strengthen the leadership, operational and clinical capabilities of current and emerging CMOs and other clinical leaders through executive development, peer mentorship and practical learning opportunities tailored to the unique challenges facing CHCs. "Community Health Centers play a critical role in delivering care to millions of people across the country," said Bryan Vaughn, executive vice president and president of Diagnostics at Labcorp. "Through our work with NACHC, Labcorp is investing in the future of community-based healthcare by helping develop the next generation of clinical leaders and leveraging laboratory data to enhance care delivery and improve outcomes for patients." About Labcorp Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. Labcorp provide insights and advance science to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025 and performed more than 750 million tests for patients around the world. Learn more at www.labcorp.comopens in a new tab. About NACHC NACHC's mission is to champion Community Health Centers delivering affordable, effective, comprehensive primary care that is community-driven and improves health for all. For more information, visit www.nachc.org.opens in a new tab SOURCE Labcorp Labcorp Media, Alissa Lawver, [email protected]; Labcorp Investors, Dewey Steadman, [email protected]; NACHC Contact, Michael King, [email protected]
Labcorp CEO Adam Schechter sold 4,669 shares of the company for approximately $1.5 million on 11 August 2026, according to an SEC filing. The transaction was executed under a Rule 10b5-1 plan, which allows insiders to sell shares on a predetermined schedule whilst complying with insider trading regulations. The sale represented approximately 4% of Schechter's direct holdings. He continues to hold 102,565 shares valued at $33 million as of the transaction date. Labcorp shares achieved a 21% total return over the 12 months ending on the transaction date. Labcorp Holdings provides diagnostic laboratory services and drug development support. The company has 71,000 employees and a market capitalisation of $26.4 billion.
Labcorp Holdings is showing improved growth in the second half of 2026, with stronger revenue, wider margins, and raised full-year guidance. Specialty testing in oncology, women's health, and autoimmune disease delivered double-digit revenue growth in the first half. The company's 2026 revenues are expected to grow 5.6% year over year. Second-quarter adjusted operating margin expanded 70 basis points year over year to 15.8%. Diagnostics margin rose 50 basis points to 18%, whilst Biopharma Laboratory Services margin increased 130 basis points to 17%. The gains came from organic growth, operating efficiencies, and technology initiatives including automation and artificial intelligence. However, the stock now trades at 16.7 times forward 12-month earnings, above both its five-year median of 14.4 times and its industry multiple of 16.2 times, leaving limited room for execution errors.
Labcorp announced that the US Food and Drug Administration has approved its PGDx elio tissue complete CDx as a companion diagnostic for advanced melanoma patients. The test identifies patients with certain BRAF variants who may benefit from FDA-approved BRAF inhibitors and BRAF/MEK inhibitor combination therapies. Melanoma is the deadliest form of skin cancer, with a five-year survival rate of just 16% for stage IV patients. Targeted therapies offer an important treatment option for patients whose tumours have BRAF alterations. The companion diagnostic is approved for use by qualified healthcare professionals across hospitals and clinical laboratories. As a kit-based solution, it can be implemented directly within hospitals and health systems, expanding testing access whilst enabling organisations to retain samples for future clinical research.